Detailed positive results from the DESTINY-Breast06 phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as IHC 0 with membrane staining] expression) following one or more lines of endocrine therapy.Â
Bristol Myers Squibb presented results from the phase III CheckMate-9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to investigator’s choice of lenvatinib or sorafenib as a first-line treatment for patients with unresectable hepatocellular carcinoma. Results from the study were featured in a late-breaking oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting.Â
Bristol Myers Squibb announced results from three updated analyses from the CheckMate-77T, CheckMate-816, and CheckMate-9LA studies supporting Opdivo (nivolumab) and Opdivo-based combinations in early stage and advanced non-small cell lung cancer. Data were presented at the 2024 American Society of Clinical Oncology Annual Meeting.
According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer.Â
The novel anti-CD19 autologous CAR T-cell therapy obecabtagene autoleucel achieved durable remissions in 40% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia without a subsequent stem cell transplant, according to results from the phase Ib/II FELIX clinical trial presented by Elias Jabbour, professor of leukemia at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.Â
When combined with azacitidine, a 7-day course of venetoclax demonstrated similar remission rates and was more tolerable compared to the standard 28-day course for older or chemotherapy-ineligible patients with newly diagnosed acute myeloid leukemia. Results from the retrospective multi-center analysis were presented by Alexandre Bazinet, assistant professor of leukemia at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
Preliminary data from a phase I study evaluating the novel antibody-drug conjugate M9140 demonstrated encouraging activity in heavily pretreated patients with advanced colorectal cancer. The study was presented by principal investigator Scott Kopetz, professor of gastrointestinal medical oncology and associate vice president for Translational Integration at MD Anderson, at the 2024 American Society of Clinical Oncology Annual Meeting.
Preliminary data from the first-in-human phase I trial of RO7623066—a first-in-class inhibitor of ubiquitin-specific peptidase 1—show a promising safety profile as a single agent and signs of early anti-tumor activity for patients with advanced solid tumors. The data were presented by Timothy Yap, professor of investigational cancer therapeutics and vice president and head of clinical development in MD Anderson’s Therapeutics Discovery division, at the 2024 American Society of Clinical Oncology Annual Meeting.
Purple Biotech Ltd. announced positive interim data from its randomized, controlled, open label, multicenter phase II study of CM24 in second-line metastatic pancreatic ductal adenocarcinoma presented at a late-breaking abstract poster presentation at the 2024 American Society of Clinical Oncology Annual Meeting. Â
Researchers at UNC Lineberger Comprehensive Cancer Center and colleagues have established the most comprehensive molecular portrait of the workings of KRAS and how its activities impact pancreatic cancer outcomes.Â
